81 related articles for article (PubMed ID: 15330184)
21. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
[TBL] [Abstract][Full Text] [Related]
22. Soluble angiopoietin receptor Tie-2 in patients with acute myocardial infarction and its effects on angiogenesis.
Wang C; Fu P; Li H; Gao R; Xiu R
Clin Hemorheol Microcirc; 2005; 33(1):1-10. PubMed ID: 16037627
[TBL] [Abstract][Full Text] [Related]
23. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
24. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies.
Quartarone E; Alonci A; Allegra A; Bellomo G; Calabrò L; D'Angelo A; Del Fabro V; Grasso A; Cincotta M; Musolino C
Eur J Haematol; 2006 Dec; 77(6):480-5. PubMed ID: 16978237
[TBL] [Abstract][Full Text] [Related]
25. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.
Kirman I; Belizon A; Balik E; Feingold D; Arnell T; Horst P; Kumara S; Cekic V; Jain S; Nasar A; Whelan RL
Eur J Surg Oncol; 2007 Dec; 33(10):1169-76. PubMed ID: 17512160
[TBL] [Abstract][Full Text] [Related]
26. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Caine GJ; Stonelake PS; Lip GY; Blann AD
Cancer Lett; 2007 Apr; 248(1):131-6. PubMed ID: 16891056
[TBL] [Abstract][Full Text] [Related]
27. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
28. Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury.
Perkins GD; Roberts J; McAuley DF; Armstrong L; Millar A; Gao F; Thickett DR
Thorax; 2005 Feb; 60(2):153-8. PubMed ID: 15681505
[TBL] [Abstract][Full Text] [Related]
29. Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Kuramochi H; Lenz HJ; Danenberg KD; Danenberg PV
Ann Surg Oncol; 2008 Apr; 15(4):1232-8. PubMed ID: 18239970
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
31. Targets and elective colorectal cancer: outcome and symptom delay at surgical resection.
Bharucha S; Hughes S; Kenyon V; Anderson ID; Carlson GL; Scott NA
Colorectal Dis; 2005 Mar; 7(2):169-71. PubMed ID: 15720357
[TBL] [Abstract][Full Text] [Related]
32. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
35. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Zaman K; Driscoll R; Hahn D; Werffeli P; Goodman SL; Bauer J; Leyvraz S; Lejeune F; Stupp R; Rüegg C
Int J Cancer; 2006 Feb; 118(3):755-64. PubMed ID: 16114015
[TBL] [Abstract][Full Text] [Related]
36. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
37. Palliative laparoscopic resections for Stage IV colorectal cancer.
Moloo H; Bédard EL; Poulin EC; Mamazza J; Grégoire R; Schlachta CM
Dis Colon Rectum; 2006 Feb; 49(2):213-8. PubMed ID: 16416080
[TBL] [Abstract][Full Text] [Related]
38. Surgeon's awareness of the synchronous liver metastases during colorectal cancer resection may affect outcome.
Hamady ZZ; Malik HZ; Alwan N; Wyatt JI; Prasad KR; Toogood GJ; Lodge JP
Eur J Surg Oncol; 2008 Feb; 34(2):180-4. PubMed ID: 17983724
[TBL] [Abstract][Full Text] [Related]
39. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
40. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]